

EFIC 2022 – Conflict of Interest – Planner-based

First Name	Last Name	Institution	Country	Type of COI	COI Description	COI Source
Nadine	Attal	University Versailles Saint-Quentin	France	Financial	Honoraria from Pfizer, Grunenthal, Merz, Biogen, Novartis for advisory boards or scientific advice over the past 36 months.	Pfizer, Grunenthal, Merz, Biogen, Novartis
Ralf	Baron	Division of Neurological Pain Research and Therapy, Department of Neurology, Universitätsklinikum Schleswig-Holstein	Germany	Financial	Prof. Baron reports grants from EU Projects: „Europain“ (115007). DOLORisk (633491). IMI Paincare (777500).	„Europain“ (115007). DOLORisk (633491). IMI Paincare (777500).
Chad	Brummett	University of Michigan	United States	Financial	NIH Common Fund UM1 NS118922, NIAMS/NIH: R01 AR060392; P50 AR070600, NIDA/NIH: R01 DA038261; R01 DA042859, Michigan Department of Health and Human Services, SAMHSA, CDC, Precision Health Initiative, University of Michigan Department of Anesthesiology, Patent for the use of peripheral perineural dexmedetomidine alone and in combination with local	NIH, Heron Therapeutics, Vertex Pharmaceuticals and Alosa Health

EFIC 2022 – Conflict of Interest – Planner-based

					anesthetics. Application number 12/791,506; Issue Date 4/2/13; Patent Number 8410140, Consultant- Heron Therapeutics, Vertex Pharmaceuticals and Alosa Health	
Felicia	Cox	Royal Brompton & Harefield Hospitals	United Kingdom	Academic	Founder member Pain Nurse Network. Honorary Member British Pain Society. Fellow Royal College of Nursing.	British Pain Society. Fellow Royal College of Nursing
David	Finn	National University of Ireland Galway	Ireland	Financial	Research grant support from B. Braun Ltd, Shionogi Ltd and Alkermes Inc. Honorarium from GW Pharmaceuticals.	B. Braun Ltd, Shionogi Ltd and Alkermes Inc. , GW Pharmaceuticals.
Julia	Forstenpointner	Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel	Germany	Financial	J. Forstenpointner reports a grant (FO 1311/1-1) from the German Research Foundation (DFG); personal fees and non- financial support from Grünenthal GmbH and Sanofi Genzyme GmbH; personal fees from Bayer; non-financial support from Novartis.	German Research Foundation (DFG), Grünenthal GmbH and Sanofi Genzyme GmbH, Bayer, Novartis.

EFIC 2022 – Conflict of Interest – Planner-based

Thomas	Graven-Nielsen	Center for Neuroplasticity and Pain (CNAP), Aalborg University	Denmark	Academic	Nocetech (cuff algometer) is partly owned by Aalborg University. Cuff algometry data will be presented.	Nocetech
Lauren C	Heathcote	Stanford University School of Medicine	United States	Financial	I have received consulting fees from Blue Note Therapeutics. None of the data presented in my talk is related to this consultancy work.	Blue Note Therapeutics
Kim	Henriksen	Nordic Bioscience	Denmark	Academic	Employee of Nordic Bioscience, a company focused on biomarker and drug development	Nordic Bioscience
Urike	Kaiser	Medical Faculty Carl Gustav Carus, Technical University Dresden, Germany	Germany	Financial	General and personal funding for VAPAIN and EVaSIMST as principal investigator	VAPAIN and EVaSIMST
Angelika	Lampert	RWTH Aachen	Germany	Academic/Financial	Research contract with Hoffmann-La Roche and Grünenthal, consulting agreement with Grünenthal.	Hoffmann-La Roche and Grünenthal
Antoinette	Maassen van den Brink	Erasmus MC	Netherlands	Financial	I have received research grants and/or speaker fees from Amgen/Novartis, Abbvie, Lilly and Teva.	Amgen/Novartis, Abbvie, Lilly and Teva.
Manjit	Matharu	University college London Queen square institute of	United Kingdom	Academic/Financial	Dr Matharu is chair of the medical advisory	CSF Leak Association, AbbVie, Autonomic

EFIC 2022 – Conflict of Interest – Planner-based

		Neurology and the National Hospital for Neurology and Neurosurgery				board of the CSF Leak Association; has served on advisory boards for AbbVie, Autonomic Technologies Inc, Eli Lilly, Novartis, Lundbeck, Pfizer, Salvia and TEVA; has received payment for educational presentations from AbbVie, electroCore, Eli Lilly, Novartis and TEVA; has received grants from Abbott, Medtronic and electroCore; and has a patent on system and method for diagnosing and treating headaches (WO2018051103A1, issued).	Technologies Inc, Eli Lilly, Novartis, Lundbeck, Pfizer, Salvia, TEVA, electroCore, Abbott, Medtronic.
Bart	Morlion	KU Leuven	Belgium	Financial	Over the last 5 years I received fees for services	Grünenthal, Lilly, Mundipharma, Pfizer, Krka, Ache, Sandoz	
					<ul style="list-style-type: none"> • Speaker’s activities: Grünenthal, Lilly, Mundipharma, Pfizer, Krka, Ache, Sandoz • Consultancy activities: Boehringer 	Boehringer Ingelheim, Grünenthal, Janssen, Mundipharma, TEVA, GSK, Kyowa-Kirin, Pfizer, Lilly, Boston Scientific, Reckitt & Benckiser	

EFIC 2022 – Conflict of Interest – Planner-based

					Ingelheim, Grünenthal, Janssen, Mundipharma, TEVA, GSK, Kyowa-Kirin, Pfizer, Lilly, Boston Scientific, Reckitt & Benckiser	
Romina	Nassini	University of Florence	Italy	Academic	Romina Nassini is a founding scientist of FloNext Srl.	FloNext Srl
Emilie	Olie	University of Montpellier	France	Financial	Honoraria , fees for participation to congress, consulting, symposia speaker : Janssen Cilag , Lundbeck, Otsuka, Servier, Astra Zeneca, institut UPSA douleur, Fondation Avenir, FRM, PI in Aspire 2 trial	Janssen Cilag , Lundbeck, Otsuka, Servier, Astra Zeneca, institut UPSA douleur, Fondation Avenir, FRM, PI in Aspire 2 trial
Esther	Pogatzki-Zahn	Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital Muenster	Germany	Academic/Financial	E.M.P.-Z. received financial support from Grunenthal for research activities, advisory and lecture fees from Grünenthal, Novartis and Mundipharma. In addition, she receives scientific support from the German Research Foundation (DFG), the	Grünenthal, Novartis and Mundipharma, German Research Foundation (DFG), the Federal Ministry of Education and Research (BMBF), the Federal Joint Committee (G-BA) and the Innovative Medicines Initiative 2 Joint , the European

EFIC 2022 – Conflict of Interest – Planner-based

					Federal Ministry of Education and Research (BMBF), the Federal Joint Committee (G-BA) and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777500. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. All money went to the institutions (WWU/UKM) E.M.P.-Z. is working for.	Union's Horizon 2020 research and innovation programme and EFPIA. All money went to the institutions (WWU/UKM) E.M.P.-Z. is working for.
Theodore J.	Price	The University of Texas at Dallas, School of Behavioral and Brain Sciences	United States	Academic	Co-Founder of Doloromics	Doloromics
Sakina	Rizvi	University of Toronto	Canada	Financial	SJR has received research funding or consultancy fees from Pfizer Canada, Janssen, Allergan, Neurocrine and Takeda.	Pfizer Canada, Janssen, Allergan, Neurocrine and Takeda.
Cormac	Ryan	Teesside University	United Kingdom	Academic	Professor Cormac Ryan is a named inventor on a patent for a sensory discrimination training	Flippin' Pain campaign

EFIC 2022 – Conflict of Interest – Planner-based

					device for the treatment of phantom limb pain. Professor Ryan is the community pain champion for the Flippin' Pain campaign, for which his University receives consultancy fees, however, Professor Ryan receives no payment.	
Ulrike M.	Stamer	University of Bern, Inselspital	Switzerland	Financial	U. Stamer received fees and reimbursement for travel costs from Sanofi Avantis, Sintetica and Grünenthal paid to her institution.	Sanofi Avantis, Sintetica and Grünenthal
Tasha	Stanton	University of South Australia	Australia	Financial	T. Stanton received payment for lectures relating to pain and rehabilitation.	Not disclosed
Brendon	Stubbs	Institute of Psychiatry, Psychology and Neuroscience, King's College London	United Kingdom	Financial	Brendon Stubbs is funded by an NIHR Advanced Fellowship (NIHR301206, 2021-2026) to investigate pain management and develop better pain interventions for people with serious mental illness.	NIHR Advanced Fellowship
Rolf-Detlef	Treede	Medical Faculty Mannheim of Heidelberg University	Germany	Academic/Financial	Disclosures (2009-2021):	Astellas, Astra-Zeneca, Bayerfeind, Bayer,

EFIC 2022 – Conflict of Interest – Planner-based

Andrea	Truini	Sapienza University	Italy	Financial	<p>Employment: Heidelberg University Advisor: Astellas, Astra-Zeneca, Bauerfeind, Bayer, Boehringer Ingelheim, Galderma, Glaxo Smith Kline, Grünenthal, Lilly, Merz, Merck-Sharpe & Dohme, Novartis, Pfizer, Sanofi, Schwarz-Pharma/UCB Shareholder: none Honoraria: lectures for Astellas, AWD, Boehringer Ingelheim, Dr. Kade, Nycomed, Grünenthal, Lilly, Mundipharma, Pfizer, Schwarz-Pharma/UCB, Medichem, Teva Grants: BMBF, DFG, EU, NIH, Dr. Kade, Boehringer Ingelheim, Astellas, AbbVie, Bayer Reviewer: several public funding sources</p>	<p>Boehringer Ingelheim, Galderma, Glaxo Smith Kline, Grünenthal, Lilly, Merz, Merck-Sharpe & Dohme, Novartis, Pfizer, Sanofi, Schwarz-Pharma/UCB, Dr. Kade, Nycomed, Grünenthal, Mundipharma, Medichem, Teva, BMBF, DFG, EU, NIH, AbbVie</p>
					<p>I received consulting fees or payment for lectures from Angelini, Grünenthal, Pfizer, Eliem Therapeutics, Viatris.</p>	<p>Angelini, Grünenthal, Pfizer, Eliem Therapeutics, Viatris.</p>

EFIC 2022 – Conflict of Interest – Planner-based

Jan	Vollert	Imperial College London	United Kingdom	Financial	JV has received consultancy fees from Casquar, Vertex Pharmaceuticals, and Embody Orthopaedics, and speaking fees from Bioevents.	Casquar, Vertex Pharmaceuticals, Embody Orthopaedics, Bioevents.
-----	---------	-------------------------	----------------	-----------	---	--